Clinical Translation: Targeting the Estrogen Receptor

Area of Science:

• Oncology
• Endocrinology
• Medicinal Chemistry

Background:

• Estrogen Receptor alpha (ERα) has been a successful oncology drug target for over 40 years, starting with tamoxifen for ER-positive breast cancer.
• The development of aromatase inhibitors and fulvestrant further advanced ERα-targeted therapies.
• Interest in novel ERα therapeutics waned in the early 2000s but has recently resurged.

Purpose of the Study:

• To describe the history and science behind the evolving landscape of ERα targeting in breast cancer.
• To highlight the re-emergence of ERα as a drug target in oncology.
• To discuss advances in medicinal chemistry enabling improved ERα-targeted therapeutics.

Main Methods:

• Review of historical data on ERα-targeted therapies.
• Analysis of recent clinical investigations of novel ERα-targeting agents.
• Discussion of medicinal chemistry advancements in drug design.

Main Results:

• At least eight new molecular entities targeting ERα are in active clinical investigation.
• Discovery of ERα mutations as a resistance mechanism has spurred renewed interest.
• Advances in medicinal chemistry have led to potent ERα antagonists with improved drug-like properties.

Conclusions:

• ERα remains a critical target in breast cancer treatment.
• Novel ERα-targeted therapies are under active development, offering potential for improved patient outcomes.
• Medicinal chemistry innovations are crucial for developing next-generation ERα antagonists.